Getting It Right: How Early Engagements with CDMOs Add Value to Small Biotechs

4:15 PM - 5:15 PM (PDT), Wednesday, June 15, 2022

Marwood Group estimates that there are more than 500 CDMOs globally and with more 45 large pharma and big biotech in the $10B+ Market Cap range, many emerging biotechs see themselves as small fish in a big pond when considering CDMO partners.  With the goal of getting life-changing medicines to patients in a timely, continuous fashion hovering in the background, early engagements with CDMOs can realize company goals faster but many biotechs lack the internal resources and/or expertise to identify the right partner.  This panel will highlight success stories and provide an in-depth review of questions to ask and what to look for, including the critical capabilities and an evaluation of CDMOs knowledge, when searching for a CDMO.

Sponsored By
Moderator
photo
Rathmann Professor in Bioprocessing and Director of the Amgen Bioprocessing Center
Keck Graduate Institute
Speakers
photo
Sr. Director and General Manager, MMS Operations
Thermo Fisher Scientific
photo
General Manager, Site Head
Thermo Fisher Scientific
photo
SVP, Global Manufacturing
Primmune Therapeutics